|
SONIA POULTON INTERVIEWS DR. MIKAEL NORDFORS CORRUPTED MEDICINE AND ALTERNATIVE TREATMENTS. |
70.00% |
|
Some pharmacological properties of prolonged administration of Ukrain in rodents |
50.00% |
|
Six-week treatment with Ukrain in rabbits. Part III: Serum levels of thyroid hormones |
|
|
Serum cytokines in pancreatic cancer: Correlation with outcome |
40.00% |
|
Serum calcium and the risk of prostate cancer. |
60.00% |
|
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. |
80.00% |
|
Sen. Ron Johnson Sends Letter to Sec. of Defense Demanding Information on Shockingly High COVID-19 Vaccine Injury Among Military Personnel |
100.00% |
|
Selective inhibition of in vitro cell growth by the anti-tumour drug Ukrain |
70.00% |
|
Sanguinarine-induced apoptosis in human leukemia U937 cells via Bcl-2 downregulation and caspase-3 activation. |
90.00% |
|
Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. |
80.00% |
|
Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins |
80.00% |
|
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. |
50.00% |
|
Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. |
90.00% |
|
Safety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial |
70.00% |
|
ROS production and angiogenic regulation by macrophages in response to heat therapy. |
80.00% |
|
Roles of sildenafil in enhancing drug sensitivity in cancer. |
50.00% |
|
Role of infectious agents in the emergence of malignant tumors |
90.00% |
|
Role of everolimus in the treatment of renal cell carcinoma. |
50.00% |
|
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic ca |
90.00% |
|
Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. |
60.00% |
|
Review on molecular and therapeutic potential of thymoquinone in cancer. |
60.00% |
|
Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo |
70.00% |
|
Reversal of Signs and Symptoms of a B-Cell Lymphoma in a Patient Using Only Low-Dose Naltrexone |
100.00% |
|
Retrospective study of Ukrain treatment in 203 patients with advanced-stage tumors |
90.00% |
|
Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. |
50.00% |
|
Resveratrol |
80.00% |
|
Results of Ukrain monotherapy of prostate cancer |
50.00% |
|
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. |
40.00% |
|
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer |
60.00% |
|
Response of brain metastases from breast cancer to megestrol acetate: a case report. |
80.00% |
|
Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced |
90.00% |
|
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status |
60.00% |
|
Removed from Pubmed because of suspiion of scientific fraud: Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. |
75.00% |
|
Removed from Pubmed because of suspicion of scientific fraud: Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). |
55.00% |
|
Removed because of suspicion of scientific fraud: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. |
10.00% |
|
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory |
80.00% |
|
Regional hyperthermia in high-risk soft tissue sarcomas. |
80.00% |
|
Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. |
95.00% |
|
RECURRENCE OF BRAIN TUMORS MAY BE PREVENTED WITH RUTA AND CALCAREA PHOSPHORICA |
90.00% |
|
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative.... |
|
|
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative.. |
80.00% |
|
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. |
40.00% |
|
Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119 |
70.00% |
|
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory....... |
70.00% |
|
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. |
70.00% |
|
Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus u |
50.00% |
|
Radiosurgery for spinal malignant tumors. |
70.00% |
|
Radiomodification effects of Ukrain, a cytostatic and immunomodulating drug, on intracellular glucocorticoid reception during sh |
60.00% |
|
Radiofrequency ablation |
70.00% |
|
Quality of radiosurgery for single brain metastases with respect to treatment technology: a matched-pair analysis. |
70.00% |
|
Pycnogenol may alleviate adverse effects in oncologic treatment. |
60.00% |
|
Psychodynamic psychotherapy, therapeutic touch and cancer. A review of the method of intervention and studv of 75 cases |
100.00% |
|
Psychodynamic pain management for cancer patients |
100.00% |
|
Psorinum, the anti cancer miracle from India. |
91.47% |
|
Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study. |
100.00% |
|
PSMA - Lutetium Treatment |
|
|
Proton Therapy |
70.00% |
|
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. |
70.00% |
|
Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. |
|
|
Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). |
90.00% |
|
Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador) |
80.00% |
|
Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice |
55.00% |
|
Programmed drug delivery: nanosystems for tumor targeting. |
60.00% |
|
Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. |
|
|
Prof. Meyl upptäckte DNA-vågor och Skalär Våg Biologi |
100.00% |
|
Prof. Meyl detected DNA-Wave and Scalar Wave Biology |
100.00% |
|
Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. |
80.00% |
|
Presence of nanobacteria in psammoma bodies of ovarian cancer: evidence for pathogenetic role in intratumoral biomineralization. |
80.00% |
|
Preliminary studies on the effect of Ukrain on the immunological response in patients with malignant tumours. |
60.00% |
|
Preliminary pharmacokinetic studies of Ukrain in rats |
|
|
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. |
50.00% |
|
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom |
50.00% |
|
Pre-Clinical Investigations on Ukrain |
90.00% |
|
PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation. |
70.00% |
|
Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma |
80.00% |
|
Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. |
50.00% |
|
Possible association between nanobacteria and malignant microcalcifications in breast cancer. |
80.00% |
|
Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer. |
90.00% |
|
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. |
70.00% |
|
Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients. |
80.00% |
|
Photodynamic Therapy |
70.00% |
|
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit |
70.00% |
|
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer |
70.00% |
|
Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer |
80.00% |
|
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. |
40.00% |
|
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ...... |
95.00% |
|
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. |
80.00% |
|
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. |
70.00% |
|
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. |
70.00% |
|
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr |
45.00% |
|
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the |
30.00% |
|
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered.... |
30.00% |
|
Pectin: A Bioactive Food Polysaccharide with Cancer Preventive Potential |
70.00% |
|
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities |
50.00% |
|
Pancreatic cancer stem cells - insights and perspectives. |
40.00% |
|
Outside the box--novel therapeutic strategies for glioblastoma. |
80.00% |
|
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. |
30.00% |
|
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. |
70.00% |
|
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz |
25.00% |
|
Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. |
60.00% |
